

## Supplementary Data 1

**Analysis of *IL22RA2* and cytokine gene expression by qPCR and surface expression markers by flow cytometry in CD16<sup>+</sup>/CD14<sup>+</sup> or CD16<sup>+</sup> monocytes and their corresponding derived immature and mature dendritic cells.**

We tested whether *IL22RA2* expression patterns were different in distinct monocyte subpopulations stratified according to CD14<sup>+</sup> and CD16<sup>+</sup> expression. The approach was based on an initial granulocyte and NK cell depletion, followed by CD16<sup>+</sup> selection (Miltenyi, 130-091-765) of both non-classical and intermediate monocytes, while the CD16-negative fraction was subjected to a further CD14-positive selection (Miltenyi, 130-050-201) consisting of classical monocytes. Flow cytometry graphs and scheme of this strategy are presented below (**Figure 1**).




Figure 1: CD16<sup>+</sup>/CD14<sup>+</sup> and CD16<sup>+</sup> monocyte purification analysed by flow cytometry.

In order to generate immature and mature moDCs, we cultured the purified monocytes in Mo-DC medium and matured them by treatment with IFN- $\gamma$  and then with LPS for 24h or left untreated (immature) as described in **Materials and Methods** section. Assessment of expression of surface maturation markers before and after maturation was done by flow cytometry and is summarized in the following **Figure 2**.




Figure 2: Flow cytometric analysis of *in vitro* generated monocyte-derived dendritic cells (moDCs) using the Mo-DC Differentiation Inspector. Surface markers (CD14, CD83 and CD209) expression of CD16/CD14<sup>+</sup> or CD16<sup>+</sup> moDCs were analysed. CD14=FITC; CD83=APC and CD209=PE.

We analysed expression of cytokine genes at day 0 (freshly isolated monocytes) and at day 7 (immature and matured moDCs) (**Figure 3**). Primers and probes are indicated at the end of this supplement.

*IL22RA2* levels were higher in CD16<sup>+</sup> compared to CD14<sup>+</sup> monocytes, while *IL10* and *IL6* followed opposite trends (**Figure 3**, left). However, expression of *IL22RA2*




Figure 3: *IL22RA2* and cytokine gene expression in CD16/CD14<sup>+</sup> or CD16<sup>+</sup> monocytes and in their corresponding immature and mature monocyte derived dendritic cells (moDCs) subpopulations.

increased to similar levels upon cultivation of CD16<sup>+</sup> or CD14<sup>+</sup> monocytes in Mo-DC medium (**Figure 3**, right). Maturation decreased *IL22RA2* expression in both subpopulations; nevertheless, the decrease was marked more strongly in CD16<sup>+</sup>-monocyte derived, compared to CD14<sup>+</sup>-monocyte derived DCs (**Figure 3**, right).

We further analyzed more extensive cytokine expression signatures in addition to *IL22RA2* in the corresponding moDCs. In both CD16<sup>+</sup> monocyte-derived and CD14<sup>+</sup> monocyte-derived immature DCs, we observed similar expression levels under non-stimulated conditions for *IL23A*, *IL18*, *IFNB*, *IL12B*, *IL10* and *IL20*. However, *IL22RA2* levels were modestly higher (2,5-fold increase) in CD16<sup>+</sup> moDCs, while *IL19* levels were much higher (17-fold increase) in CD14<sup>+</sup> moDCs.

When comparing IFN- $\gamma$ /LPS-stimulated mature moDCs with immature moDCs (**Table 1**), a strong induction of *IL12B* (about 120 fold increase) as well as smaller ones of *IL18* (about 8-fold increase) and *IL20* (about 2-fold increase) were observed in both CD14<sup>+</sup> and CD16<sup>+</sup> derived populations. *TGF $\beta$*  was down-regulated (about 3-fold decrease) to similar extent in both populations. However, *IL22RA2* showed a 3-fold decrease in CD16<sup>+</sup>CD14<sup>+</sup> moDCs and a 32-fold decrease in CD16<sup>+</sup> moDCs. Various other cytokines were differentially upregulated during culture with the maturation stimuli IFN- $\gamma$ /LPS. In CD16<sup>+</sup>CD14<sup>+</sup> moDCs compared to CD16<sup>+</sup> moDCs, *IFNB* (28-fold increase vs. no difference) and *IL23A* (17-fold increase vs. 5) showed higher levels of upregulation, while *IL19* (2-fold change vs. 91) and *IL10* (7-fold change vs. 41) were less strongly upregulated.

Table 1: Cytokine gene expression fold-change of mature moDCs relative to immature moDCs.

	CD14 <sup>+</sup> -monocyte derived DCs treated on D7 with IFN- $\gamma$ / LPS	CD16 <sup>+</sup> -monocyte derived DCs treated on D7 with IFN- $\gamma$ / LPS		
<i>IL12B</i>	124	114		
<i>IL19</i>	2	91		Highly increased (>10)
<i>IL10</i>	7	41		Moderately increased (<10)
<i>IFNB</i>	28	1,24		Moderately decreased (<10)
<i>IL23A</i>	17	5		Highly decreased (>10)
<i>IL18</i>	7	9		
<i>IL20</i>	2	1,5		
<i>IL22RA2</i>	2	32		
<i>TGFB</i>	3	4		

Based on these findings, our research continued in identifying the CD16<sup>+</sup> monocyte subpopulation (intermediate, non-classical or both) that expressed higher levels of *IL22RA2*, described in the main article text, but we did not further focus on the effects of maturation nor on the other cytokine genes in these 3 populations.

As shown in **Figure 8** in the main article text, we noted that although *IL22RA2* levels are monocyte-subpopulation specific, following *in vitro* culture in Mo-DC differentiation medium, these differences disappear, and therefore, CD14<sup>+</sup> moDCs are a suitable model for the study of *IL22RA2*.

### Primers and probes used in Supplementary Data 1.

Gene	Assay ID	Type	Dye	Catalog #	Company
<i>IFNB</i>	Hs01077958_s	Probe	FAM	4331182	Thermo Fisher
<i>IL12B</i>	Hs01011519_m1	Probe	FAM	4331182	Thermo Fisher
<i>IL23A</i>	Hs00900828_g1	Probe	FAM	4331182	Thermo Fisher
<i>IL6</i>	Hs00174131_m1	Probe	FAM	4331182	Thermo Fisher
<i>IL19</i>	Hs00604657_m1	Probe	FAM	4331182	Thermo Fisher
<i>IL10</i>	Hs00961622_m1	Probe	FAM	4331182	Thermo Fisher
<i>IL20</i>	Hs00218888_m1	Probe	FAM	4331182	Thermo Fisher
<i>IL22RA2</i>	Hs00364814_m1	Probe	FAM	4331182	Thermo Fisher
<i>ACTB</i>	Hs99999903_m1	Probe	VIC	4448489	Thermo Fisher
<i>IL18</i>	Hs.PT.58.25675872	Primers	-	-	IDT
<i>TGFB</i>	Hs. PT.58.22563137	Primers	-	-	IDT
<i>IL22RA2</i>	Hs.PT.58.40811	Primers			IDT
<i>ACTB</i>	Hs. PT.39a.22214847	Primers			IDT